株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ChironWells GmbHの製品パイプライン分析

ChironWells GmbH - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 319969
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ChironWells GmbHの製品パイプライン分析 ChironWells GmbH - Product Pipeline Review - 2015
出版日: 2015年12月16日 ページ情報: 英文 24 Pages
概要

ChironWells GmbHはオーストリアに本社をもつ製薬企業で、疼痛管理、免疫疾患、胃腸障害に対する治療薬を開発、販売しています。パイプライン製品にはHS731、HS378、HS198があり、うちHS731は末梢神経に作用するオピオイド系鎮痛剤で、中度から重度の急性・慢性疼痛の治療に用いられます。HS378はカルシニューリン阻害剤で、乾癬、アトピー性皮膚炎、リウマチ性関節炎などの免疫性疾患の治療に用いられます。

当レポートでは、ChironWells GmbHにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ChironWells GmbHの基本情報

  • ChironWells GmbHの概要
  • 主要情報
  • 企業情報

ChironWells GmbH:R&Dの概要

  • 主な治療範囲

ChironWells GmbH:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ChironWells GmbH:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

ChironWells GmbH:薬剤プロファイル

  • HS-198
  • HS-378
  • HS-731
  • Small Molecule for Bowel Motility Disorders
  • Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases

ChironWells GmbH:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ChironWells GmbH:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07869CDB

Summary

Global Markets Direct's, 'ChironWells GmbH - Product Pipeline Review - 2015', provides an overview of the ChironWells GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ChironWells GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ChironWells GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ChironWells GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ChironWells GmbH's pipeline products

Reasons to buy

  • Evaluate ChironWells GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ChironWells GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ChironWells GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ChironWells GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ChironWells GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ChironWells GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ChironWells GmbH Snapshot
    • ChironWells GmbH Overview
    • Key Information
    • Key Facts
  • ChironWells GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • ChironWells GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ChironWells GmbH - Pipeline Products Glance
    • ChironWells GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ChironWells GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ChironWells GmbH - Drug Profiles
    • HS-731
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HS-198
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HS-378
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize OP3 Receptor for Bowel Motility Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ChironWells GmbH - Pipeline Analysis
  • ChironWells GmbH - Pipeline Products by Target
  • ChironWells GmbH - Pipeline Products by Route of Administration
  • ChironWells GmbH - Pipeline Products by Molecule Type
  • ChironWells GmbH - Pipeline Products by Mechanism of Action
  • ChironWells GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ChironWells GmbH, Key Information
  • ChironWells GmbH, Key Facts
  • ChironWells GmbH - Pipeline by Indication, 2015
  • ChironWells GmbH - Pipeline by Stage of Development, 2015
  • ChironWells GmbH - Monotherapy Products in Pipeline, 2015
  • ChironWells GmbH - Phase I, 2015
  • ChironWells GmbH - Preclinical, 2015
  • ChironWells GmbH - Discovery, 2015
  • ChironWells GmbH - Pipeline by Target, 2015
  • ChironWells GmbH - Pipeline by Route of Administration, 2015
  • ChironWells GmbH - Pipeline by Molecule Type, 2015
  • ChironWells GmbH - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • ChironWells GmbH - Pipeline by Top 10 Indication, 2015
  • ChironWells GmbH - Pipeline by Stage of Development, 2015
  • ChironWells GmbH - Monotherapy Products in Pipeline, 2015
  • ChironWells GmbH - Pipeline by Top 10 Target, 2015
  • ChironWells GmbH - Pipeline by Top 10 Route of Administration, 2015
  • ChironWells GmbH - Pipeline by Top 10 Molecule Type, 2015
  • ChironWells GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top